

Summary of Consolidated Financial Statements for the Nine Months Ended September 30, 2023 (Japanese GAAP)

November 13, 2023

Company name Listed stock exchanges: Tokyo Listing code 6856 URL: https://www.horiba.com/int/ Representative Masayuki Adachi, President & COO TEL: (81)75-313-8121

Contact Yoshihiro Morita, Department Manager, Finance and Accounting Dept.

(Figures have been rounded down to the nearest million yen)

1. Consolidated Results for the Nine Months Ended September 30, 2023 (January 1, 2023 - September 30, 2023)

(1) Consolidated Operating Results

(Percentages represent changes from the corresponding in the previous year)

	Net Sales		Operating Income		Ordinary Income		Net Income Attributable to Owners of Parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine Months Ended 9/30/23	200,679	8.4	28,499	-0.3	29,089	-1.4	26,972	30.3
Nine Months Ended 9/30/22	185,121	20.2	28,571	43.9	29,508	48.5	20,702	50.9

(Note) Comprehensive income: FY2023Q3 44,608 million yen (25.5%) FY2022Q3 35,534 million yen (75.2%)

	Net Income Attributable to Owners of Parent per Share	Net Income Attributable to Owners of Parent per Share (Diluted)
	Yen	Yen
Nine Months Ended 9/30/23	638.32	635.22
Nine Months Ended 9/30/22	490.40	487.86

(2) Consolidated Financial Position

	Total Assets	Net Assets	Shareholders' Equity Ratio
	Millions of yen	Millions of yen	%
As of 9/30/23	441,271	274,649	62.1
As of 12/31/22	416,742	240,850	57.6

(Reference) Net assets excluding subscription rights to shares and non-controlling interests:

As of 9/30/23 273,922 million yen As of 12/31/22 240,065 million yen

2. Dividends

	Dividend per Share					
	First Second Third Year End Total					
	Yen	Yen	Yen	Yen	Yen	
FY 12/2022	-	65.00	-	180.00	245.00	
FY 12/2023	-	80.00	-			
FY 12/2023 (Forecasts)				180.00	260.00	

(Note) Changes in the latest dividend forecasts released: Yes

3. Consolidated Forecasts for the Year Ending December 31, 2023 (January 1, 2023 - December 31, 2023)

(Percentages represent changes from the previous fiscal year)

	Net Sale	s	Operating In	come	Ordinary Ind	come	Net Income Attrib to Owners of Pa		Net Income Attributable to Owners of Parent per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full Year	284,000	5.1	43,000	-6.2	43,000	-8.2	36,000	5.7	851.67

(Note) Changes in the latest business forecasts released: Yes

Notes

(1) Changes in significant subsidiaries during the period(Changes in specified subsidiaries that caused a change in the scope of consolidation): None

(2) Application of the accounting method specific to quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, accounting estimates and retrospective restatement

① Changes in accounting policies associated with revision of accounting standards: None

2 Changes in accounting policies arising from other than the above: None

3 Changes in accounting estimates: None

4 Retrospective restatement: None

(4) Number of shares outstanding (common stock)

① Shares issued (including treasury stock)

② Treasury stock

3 Average number of outstanding shares

September 30, 2023	42,532,752	December 31, 2022	42,532,752
September 30, 2023	263,029	December 31, 2022	302,553
Jan Sep., 2023	42,255,165	Jan Sep., 2022	42,214,607

Note 1. This consolidated financial report is not subject to quarterly review by certified public accountants or accounting firms.

Note 2. Appropriate use of business forecasts and other important information

The forecasts of dividend amount and business performance contained in this report have been made based on certain future assumptions, outlooks, and plans which are available at the HORIBA Group as of November 13, 2023. However, due to risks and various uncertain factors such as future business operation policies, changes in the economic environment in Japan and overseas, fluctuation of currency rates, it is possible that actual performance would vary considerably from the forecasts.

1. Qualitative Information Concerning Consolidated Results

(1) Information Concerning Consolidated Operating Results

(For details, see page 12-14, "3. Supplemental Information - HORIBA, Ltd. Financial Highlights for the Nine Months Ended September 30, 2023")

During the nine months ended September 30, 2023, HORIBA, Ltd. ("the Company") and its consolidated subsidiaries (together "the HORIBA Group" or "HORIBA" as a consolidated group) increased sales by 8.4% year-on-year to 200,679 million yen, mainly due to an increase in sales in the Automotive segment. Operating income decreased by 0.3% to 28,499 million yen and ordinary income by 1.4% to 29,089 million yen, mainly caused by a change in the product sales mix in the Scientific segment. In addition, contributed mainly by extraordinary gain on the sale of shares of subsidiaries in the first quarter of FY2023, net income attributable to owners of parent ("net income") increased by 30.3% to 26,972 million yen.

The operating results of each business segment are summarized as follows.

(Automotive Segment)

Sales of emission measurement systems in Asia and Americas, and sales in the MCT (Mechatronics) business in Europe increased. As a result, segment sales increased by 16.6% year-on-year to 48,167 million yen. On the profit side, factors including an increase in expenses driven by expanded investment in the growth areas such as hydrogen related field resulted in recording operating loss of 2,737 million yen (compared to an operating loss of 3,292 million yen in the first nine months of the previous year).

(Process & Environmental Segment)

Sales of air pollution analyzers in Europe as well as sales in the process measurement equipment business and of water quality system in Americas increased. As a result, segment sales increased by 11.9% year-on-year to 17,257 million yen and operating income increased by 44.9% to 1,422 million yen.

(Medical-Diagnostics Segment)

Sales of hematology analyzers in Asia and Americas as well as clinical chemistry analyzers and reagents in Europe and Americas increased by 8.4% year-on-year to 23,408 million yen. Operating income amounted to 229 million yen (compared to an operating loss of 21 million yen in the first nine months of the previous year).

(Semiconductor Segment)

Sales to semiconductor production equipment manufacturers increased due to the high-level of order backlogs by the previous year, while the adjustment phase continued in the semiconductor market. As a result, segment sales increased by 3.9% year-on-year to 84,556 million yen. On the profit side, operating income decreased by 1.5% to 28,822 million yen mainly caused by a temporary change in the product sales mix.

(Scientific Segment)

Mainly due to an increase in sales of Raman spectrometers in Asia, segment sales increased by 7.6% year-on-year to 27,289 million yen. On the profit side, operating income decreased by 53.9% to 762 million yen mainly caused by a change in the product sales mix.

(2) Information Concerning Consolidated Earnings Forecasts for FY2023

The consolidated earnings forecasts are summarized as follows.

Our assumption for the exchange rate has been changed from 137 yen to 141 yen against the US dollars and 148 yen to 151 yen against the euro.

Consolidated forecasts of FY2023 (Full year)

Amount: Millions of yen

	Previous Forecasts (As of Aug. 9)	Revised Forecasts (As of Nov. 13)	Changes
Net Sales	281,000	284,000	+3,000
Operating Income	41,000	43,000	+2,000
Ordinary Income	41,000	43,000	+2,000
Net Income Attributable to Owners of Parent	35,500	36,000	+500

Consolidated forecasts of FY2023 by segment (Full year)

Net Sales Amount: Millions of yen Operating Income Amount: Millions of yen

, and and			,	operating interine		, arriodite iviii	,
	Previous Forecasts (As of Aug. 9)	Revised Forecasts (As of Nov. 13)	Changes		Previous Forecasts (As of Aug. 9)	Revised Forecasts (As of Nov. 13)	Changes
Automotive	79,000	79,000	-	Automotive	500	500	-
Process & Environmental	25,000	25,000	-	Process & Environmental	2,500	2,500	-
Medical-Diagnostics	31,000	31,000	-	Medical-Diagnostics	500	500	-
Semiconductor	107,000	110,000	+3,000	Semiconductor	34,500	36,500	+2,000
Scientific	39,000	39,000	-	Scientific	3,000	3,000	-
Total	281,000	284,000	+3,000	Total	41,000	43,000	+2,000

With regard to consolidated earnings forecasts for FY2023, the Company has revised upward its Semiconductor segment forecasts for sales by 3,000 million yen and operating income by 2,000 million yen by taking into account the exchange rate trends.

This has resulted in upward revision in the overall sales forecast to 284,000 million yen and in the operating income forecast to 43,000 million yen. Due to the upward revision in operating income, the forecasts for ordinary income and net income have also been revised upward by 2,000 million yen to 43,000 million yen and by 500 million yen to 36,000 million yen respectively.

Amendments to dividend forecasts for FY2023

Amount: Yen

	Annual Dividend per Share				
Record Date	Interim	Year-end	Total		
Previous Forecasts (As of Aug. 9)		175	255		
Revised Forecasts		180	260		
Result for FY2023	80				
(Reference) Results for FY2022	65	180	245		

The Company's shareholder return policy is to set the total returns to shareholders (the combined amount of dividend payments and share buybacks) at approximately 30% of consolidated net income.

The dividend forecast for FY2023 had been 255 yen per share since the announcement of the "Summary of Consolidated Financial Statements for the Six Months Ended June 30, 2023" on August 9, 2023. However, considering the revised consolidated earnings forecasts for FY2023, the Company has amended the forecast for the year-end pershare dividend with an increase of 5 yen to 180 yen and thus revised upward the annual dividend forecast to 260 yen, including interim dividend which had already been paid.

Cautionary statement with respect to earnings forecasts

The forecasts of dividend amount and business performance contained in this report have been made based on certain future assumptions, outlooks, and plans which are available at the HORIBA Group as of November 13, 2023. However, due to risks and various uncertain factors such as future business operation policies, changes in the economic environment in Japan and overseas, fluctuation of currency rates, it is possible that actual performance would vary considerably from the forecasts.

2. Consolidated Financial Statements and Notes

(1) Consolidated Balance Sheets

Amount: Millions of yen			
	FY2022 (As of December 31, 2022)	FY2023 Third Quarter (As of September 30, 2023)	
Assets			
Current Assets:			
Cash and bank deposits	139,855	126,650	
Notes and accounts receivable - trade, and contract assets	69,818	64,528	
Marketable securities	1,499	2,000	
Merchandise and finished goods	26,447	36,119	
Work in process	21,415	29,645	
Raw materials and supplies	27,409	38,185	
Other current assets	11,422	16,238	
Allowance for doubtful accounts	(1,320)	(1,488)	
Total Current Assets	296,547	311,878	
Fixed Assets:			
Property, Plant and Equipment:			
Buildings and structures, net	54,226	57,051	
Machinery, equipment and vehicles, net	13,894	16,842	
Land	16,865	20,052	
Construction in progress	6,379	2,596	
Other property, plant and equipment, net	4,337	4,812	
Total Property, Plant and Equipment	95,702	101,355	
Intangibles:			
Goodwill	610	805	
Software	1,559	1,311	
Leasehold interests in land	616	660	
Other intangibles	806	781	
Total Intangibles	3,593	3,558	
Investments and Other Non-Current Assets:			
Investment securities	10,475	14,688	
Retirement benefit asset	690	841	
Deferred tax assets	6,715	6,779	
Other investments and other assets	3,063	2,238	
Allowance for doubtful accounts	(46)	(69)	
Total Investments and Other Non-Current Assets	20,898	24,478	
Total Fixed Assets	120,195	129,393	
Total Assets	416,742	441,271	

		Amount: Millions of yen
	FY2022	FY2023 Third Quarter
	(As of December 31, 2022)	(As of September 30, 2023)
Liabilities		
Current Liabilities:		
Trade notes and accounts payable	36,945	30,649
Short-term loans payable	12,351	5,066
Accounts payable-other	19,443	18,723
Accrued income taxes	9,133	3,537
Contract liabilities	24,632	31,223
Accrued bonuses to employees	2,003	3,311
Accrued bonuses to directors and corporate auditors	-	791
Reserve for product warranty	2,799	3,214
Other current liabilities	4,920	5,837
Total Current Liabilities	112,229	102,355
Non-Current Liabilities:		
Corporate bonds	30,000	30,000
Long-term loans payable	24,854	24,986
Deferred tax liabilities	1,270	584
Retirement benefit liability	1,547	1,922
Other non-current liabilities	5,990	6,773
Total Non-Current Liabilities	63,663	64,266
Total Liabilities	175,892	166,622
Net Assets		
Shareholders' Equity		
Common stock	12,011	12,011
Capital surplus	18,684	18,766
Retained earnings	194,000	209,990
Treasury stock	(1,193)	(1,037)
Total Shareholders' Equity	223,502	239,730
Accumulated Other Comprehensive Income		
Net unrealized holding gains or losses on securities	4,257	6,172
Foreign currency translation adjustments	12,156	27,869
Remeasurements of defined benefit plans	148	150
Total Accumulated Other Comprehensive Income	16,562	34,192
Subscription Rights to Shares	769	706
Non-Controlling Interests	15	21
Total Net Assets	240,850	274,649
Total Liabilities and Net Assets	416,742	441,271

(2) Consolidated Statements of Income and Consolidated Comprehensive Income Statements (Consolidated Statements of Income)

		Amount, willions of yen
	FY2022 Third Quarter	FY2023 Third Quarter
	(Nine Months Ended September 30, 2022)	(Nine Months Ended
Net Only		September 30, 2023)
Net Sales	185,121	200,679
Cost of Sales	106,113	113,875
Gross Income	79,007	86,804
Selling, General and Administrative Expenses	50,435	58,304
Operating Income	28,571	28,499
Non-Operating Income		
Interest income	315	1,259
Dividend income	158	170
Foreign exchange gains	568	-
Subsidy income	102	112
Other	330	334
Total Non-Operating Income	1,475	1,878
Non-Operating Expenses		
Interest expenses	457	527
Foreign exchange losses	-	683
Other	81	77
Total Non-Operating Expenses	539	1,288
Ordinary Income	29,508	29,089
Extraordinary Gain		
Gain on sales of fixed assets	494	34
Gain on sales of investment securities	20	-
Gain on sale of shares of subsidiaries	-	6,507
Gain on reversal of share acquisition rights	1	-
Total Extraordinary Gain	516	6,542
Extraordinary Losses		
Loss on sales of fixed assets	0	-
Loss on disposal of fixed assets	106	44
Loss on sale of investment securities	0	0
Loss on valuation of investment securities	_	21
Total Extraordinary Losses	106	65
Income before Income Taxes	29,918	35,565
Income taxes (current)	10,295	9,816
Income taxes (deferred)	(1,066)	(1,226)
Total Income Taxes	9,228	8,590
Net Income	20,689	26,975
Profit (loss) attributable to non-controlling interests	(12)	3
Net Income Attributable to Owners of Parent	20,702	26,972

(Consolidated Statements of Comprehensive Income)

	FY2022 Third Quarter	FY2023 Third Quarter
	(Nine Months Ended	(Nine Months Ended
	September 30, 2022)	September 30, 2023)
Net Income	20,689	26,975
Other Comprehensive Income		
Net unrealized holding gains or losses on securities	(1,570)	1,914
Foreign currency translation adjustments	16,411	15,537
Remeasurements of defined benefit plans	4	1
Share of other comprehensive income of entities accounted for		178
using equity method	_	170
Total Other Comprehensive Income	14,845	17,632
Comprehensive Income	35,534	44,608
(Breakdown of comprehensive income)		
Comprehensive income attributable to owners of parent	35,544	44,602
Comprehensive income attributable to non-controlling interests	(9)	6

(3) Notes to Consolidated Financial Statements

Application of special accounting for preparing quarterly consolidated financial statement (Calculation method for tax expenses)

The Company and its domestic consolidated subsidiaries calculated income tax expenses by multiplying quarterly income before income taxes by reasonably estimated annual effective tax rate. This tax rate was reasonably estimated after applying the deferred tax accounting to the annual income before income taxes.

Additional information

(Application of the Practical Solution on the Accounting and Disclosure Under the Group Tax Sharing System)

The Company and its domestic consolidated subsidiaries have transitioned from the consolidated taxation system to the group tax sharing system from the beginning of the first quarter of FY2023. Accordingly, the accounting procedures and disclosure of corporate and local income taxes and tax effect accounting are accounted for and disclosed in accordance with the "Practical Solution on the Accounting and Disclosure Under the Group Tax Sharing System" (ASBJ Practical Issues Task Force No. 42, August 12, 2021; hereinafter, "Practical Solution No. 42"). Pursuant to the provision of Paragraph 32 (1) of Practical Solution No. 42, the Company has assumed that there is no impact of the change in accounting policy due to the application of Practical Solution No. 42.

Business divestiture

In the first quarter of FY2023, HORIBA MIRA Limited (U.K.) (hereinafter MIRA), a consolidated subsidiary of the Company, sold part of the shares of MIRA UGV Limited (U.K.) (hereinafter UGV) owned by MIRA to Iveco Defence Vehicles S.p.A. (Italy) (hereinafter IDV). As a result, UGV is no longer a consolidated subsidiary and has become an equity-method affiliate.

1. Outline of business divestiture

(1) Name of the acquiring entity

Iveco Defence Vehicles S.p.A (Italy)

(2) Content of divestiture business

Unmanned Ground Vehicle development engineering services for the defense industry

(3) Main reasons for business divestiture

MIRA has provided Unmanned Ground Vehicle development engineering services for the defense industry. Taking a comprehensive view of the future prospects of the entire HORIBA Group, HORIBA decided to transfer part of the shares of UGV to IDV, in order to concentrate management resources of the Automotive segment on field of consumer vehicles such as passenger cars and heavy-duty vehicles.

(4) Date of divestiture

February 1, 2023

(5) Overviews of transaction including legal form

Share transfer which the consideration received is cash.

2. Outline of accounting treatment

Amount of gain or loss on transfer

Gain on sale of shares of subsidiaries: 6,507 million yen

The difference between the book value of the transferred shares on the consolidated basis and the transferred amount is recorded as gain on sale of shares of subsidiaries. It includes 1,359 million yen as gain on valuation of shares of associates.

3. Reportable segment that includes the consolidated subsidiary to be transferred

Automotive segment

4. Approximate amount of profit or loss related to the divested business recorded in the consolidated statements of income for the nine months ended September 30, 2023

Sales: 22 million yen

Operating loss: 26 million yen

3. Supplemental Information

HORIBA, Ltd. Financial Highlights for the Nine Months Ended September 30, 2023

1. Consolidated Financial	Results						Amount : Mil	lions of yen
	12/2022 Results	12/2023 Results	Chan	ges	12/2022 Results	12/2023 Forecasts	Chan	ges
	3Q (9 Months)	3Q (9 Months)	Amount	Ratio	Full year	Full year	Amount	Ratio
Net Sales	185,121	200,679	+15,558	+8.4%	270,133	284,000	+13,866	+5.1%
Operating Income	28,571	28,499	-72	-0.3%	45,843	43,000	-2,843	-6.2%
Operating Income Ratio	15.4%	14.2%	-1.2P		17.0%	15.1%	-1.9P	
Ordinary Income	29,508	29,089	-419	-1.4%	46,860	43,000	-3,860	-8.2%
Ordinary Income Ratio	15.9%	14.5%	-1.4P		17.3%	15.1%	-2.2P	
Net Income Attributable to Owners of Parent	20,702	26,972	+6,270	+30.3%	34,072	36,000	+1,927	+5.7%
Net Income Ratio	11.2%	13.4%	+2.2P		12.6%	12.7%	+0.1P	
US\$	128.30	138.24	+9.94		131.62	141.00	+9.38	
Euro	136.05	149.77	+13.72		138.14	151.00	+12.86	

2. Consolidated Segment	Results				Amount : Mi	llions of yen					
Net Sales	12/2022 Results	Changes		Changes		Changes			12/2023 Forecasts	Chan	ges
	3Q (9 Months)	3Q (9 Months)	Amount	Ratio	Full year	Full year	Amount	Ratio			
Automotive	41,320	48,167	+6,846	+16.6%	67,524	79,000	+11,475	+17.0%			
Process&Environmental	15,425	17,257	+1,832	+11.9%	22,541	25,000	+2,458	+10.9%			
Medical-Diagnostics	21,588	23,408	+1,819	+8.4%	29,753	31,000	+1,246	+4.2%			
Semiconductor	81,416	84,556	+3,140	+3.9%	114,075	110,000	-4,075	-3.6%			
Scientific	25,370	27,289	+1,918	+7.6%	36,239	39,000	+2,760	+7.6%			
Total	185,121	200,679	+15,558	+8.4%	270,133	284,000	+13,866	+5.1%			

Operating Income	12/2022 Results	12/2023 Changes		12/2022 12/2023 Results Forecasts		Changes		
	3Q (9 Months)	3Q (9 Months)	Amount	Ratio	Full year	Full year	Amount	Ratio
Automotive	(3,292)	(2,737)	+554	-	(667)	500	+1,167	-
Process&Environmental	981	1,422	+440	+44.9%	2,101	2,500	+398	+19.0%
Medical-Diagnostics	(21)	229	+251	-	(99)	500	+599	-
Semiconductor	29,248	28,822	-426	-1.5%	42,005	36,500	-5,505	-13.1%
Scientific	1,655	762	-893	-53.9%	2,503	3,000	+496	+19.8%
Total	28,571	28,499	-72	-0.3%	45,843	43,000	-2,843	-6.2%

3. Consolidated Segment Sales by Destination

3. Consolidated Segr	12/2022	12/2023	Chan	ges	12/2022	12/2023	Chan	ges
	Results	Results	A	D-#-	Results	Forecasts	A	D-#-
	3Q (9 Months)	3Q (9 Months)	Amount	Ratio	Full year	Full year	Amount	Ratio
Automotive	41,320	48,167	+6,846	+16.6%	67,524	79,000	+11,475	+17.0%
Japan	11,170	10,365	-805	-7.2%	16,555	16,500	-55	-0.3%
Asia	8,093	10,658	+2,564	+31.7%	14,339	20,300	+5,960	+41.6%
Americas	4,142	5,701	+1,558	+37.6%	8,110	10,900	+2,789	+34.4%
Europe	17,914	21,442	+3,528	+19.7%	28,518	31,300	+2,781	+9.8%
Process&Environmental	15,425	17,257	+1,832	+11.9%	22,541	25,000	+2,458	+10.9%
Japan	7,702	8,303	+601	+7.8%	10,861	11,800	+938	+8.6%
Asia	3,775	3,706	-68	-1.8%	5,585	6,000	+414	+7.4%
Americas	2,103	2,602	+498	+23.7%	3,002	3,000	-2	-0.1%
Europe	1,844	2,645	+801	+43.4%	3,092	4,200	+1,107	+35.8%
Medical-Diagnostics	21,588	23,408	+1,819	+8.4%	29,753	31,000	+1,246	+4.2%
Japan	4,861	5,114	+253	+5.2%	6,363	6,700	+336	+5.3%
Asia	5,109	5,499	+389	+7.6%	7,102	7,500	+397	+5.6%
Americas	4,670	5,240	+569	+12.2%	6,517	7,000	+482	+7.4%
Europe	6,946	7,554	+607	+8.7%	9,769	9,800	+30	+0.3%
Semiconductor	81,416	84,556	+3,140	+3.9%	114,075	110,000	-4,075	-3.6%
Japan	23,801	20,677	-3,123	-13.1%	32,469	26,000	-6,469	-19.9%
Asia	42,683	51,247	+8,563	+20.1%	59,509	67,400	+7,890	+13.3%
Americas	10,340	6,807	-3,533	-34.2%	15,269	9,400	-5,869	-38.4%
Europe	4,590	5,824	+1,234	+26.9%	6,827	7,200	+372	+5.5%
Scientific	25,370	27,289	+1,918	+7.6%	36,239	39,000	+2,760	+7.6%
Japan	5,138	5,562	+423	+8.2%	7,117	8,000	+882	+12.4%
Asia	7,954	9,733	+1,778	+22.4%	11,935	14,400	+2,464	+20.6%
Americas	7,808	7,259	-548	-7.0%	10,460	9,200	-1,260	-12.0%
Europe	4,469	4,733	+264	+5.9%	6,725	7,400	+674	+10.0%
Total	185,121	200,679	+15,558	+8.4%	270,133	284,000	+13,866	+5.1%
Japan	52,674	50,023	-2,650	-5.0%	73,367	69,000	-4,367	-6.0%
Asia	67,616	80,844	+13,227	+19.6%	98,472	115,600	+17,127	+17.4%
Americas	29,065	27,610	-1,455	-5.0%	43,360	39,500	-3,860	-8.9%
Europe	35,764	42,201	+6,436	+18.0%	54,933	59,900	+4,966	+9.0%

4. (Capital	Expenditures,	Depreciation	n and R&D	Expenses
------	---------	---------------	--------------	-----------	----------

4. Capital Expenditures, Depre	ciation and R&D Exper	nses	Amount : Millions of yen			
	12/20	022	12/2	2023		
	3Q (9 Months)	Full-year Results	3Q (9 Months)	Full-year Forecasts		
Capital Expenditures (*1)	7,480	12,565	6,098	11,500		
Depreciation (*2)	8,397	11,349	9,334	12,000		
R&D Expenses	13,261	18,585	15,063	21,000		

^(*1) Capital Expenditures are investments in tangible and intangible fixed assets. (*2) Amortization of goodwill is included in depreciation.

_	O 1: -1 - 4	 	D I4 -	/ O	Comparison)
~	Longollagier	ı ⊨ınancıaı	RACILITE	// HISTARIN	i amnarieani

		12/2022 Results			12/2023			
	1Q	2Q	3Q	4Q	1Q Results	2Q Results	3Q Results	4Q Forecasts
Net Sales	55,510	59,454	70,156	85,012	65,854	65,251	69,574	83,320
Operating Income	8,605	7,654	12,311	17,271	10,450	7,387	10,660	14,500
Operating Income Ratio	15.5%	12.9%	17.5%	20.3%	15.9%	11.3%	15.3%	17.4%
Ordinary Income	8,743	8,041	12,723	17,351	10,320	7,803	10,964	13,910
Ordinary Income Ratio	15.8%	13.5%	18.1%	20.4%	15.7%	12.0%	15.8%	16.7%
Net Income Attributable to Owners of Parent	5,721	5,518	9,461	13,370	13,556	5,449	7,966	9,027
Net Income Ratio	10.3%	9.3%	13.5%	15.7%	20.6%	8.4%	11.4%	10.8%

_	A	•	- "	'	• • •	
h.	Consolidated	Seament	Results	(Quarterly	Comparison	1

6. Consolidated Segment Results (Quarterly Comparison)					Amount : Millions of yen				
Net Sales	12/2022 Results			12/2023					
	1Q	2Q	3Q	4Q	1Q Results	2Q Results	3Q Results	4Q Forecasts	
Automotive	13,675	12,013	15,632	26,203	15,943	14,602	17,621	30,832	
Process&Environmental	4,788	5,403	5,233	7,116	5,404	5,931	5,921	7,742	
Medical-Diagnostics	6,650	7,022	7,914	8,165	7,351	8,241	7,815	7,591	
Semiconductor	22,225	27,195	31,994	32,659	28,988	27,237	28,330	25,443	
Scientific	8,169	7,819	9,380	10,868	8,166	9,238	9,884	11,710	
Total	55,510	59,454	70,156	85,012	65,854	65,251	69,574	83,320	

	12/2022 Results				12/2023			
Operating Income	1Q	2Q	3Q	4Q	1Q Results	2Q Results	3Q Results	4Q Forecasts
Automotive	133	(1,895)	(1,530)	2,624	330	(2,490)	(577)	3,237
Process&Environmental	453	184	343	1,119	529	387	505	1,077
Medical-Diagnostics	154	(316)	140	(77)	(43)	221	51	270
Semiconductor	7,180	9,600	12,468	12,757	9,707	8,981	10,132	7,677
Scientific	683	82	890	848	(73)	286	549	2,237
Total	8,605	7,654	12,311	17,271	10,450	7,387	10,660	14,500
Total	8,605	7,654	12,311	17,271	10,450	7,387	10,660	14,5

 $\frac{Contact}{IR \cdot ESG, Corporate \ Planning \ Office, \ Group \ Strategy \ Division, \ HORIBA, \ Ltd. \ E-mail: ir-info@horiba.com}$